Slipman C W, Lipetz J S, Plastaras C T, Jackson H B, Vresilovic E J, Lenrow D A, Braverman D L
The Penn Spine Center, Department of Rehabilitation Medicine, Philadelphia 19104, USA.
Am J Phys Med Rehabil. 2001 Jun;80(6):425-32. doi: 10.1097/00002060-200106000-00007.
To investigate the outcomes resulting from the use of fluoroscopically guided therapeutic sacroiliac joint injections in patients with sacroiliac joint syndrome.
A retrospective study design with independent clinical review was utilized. Thirty-one patients were included; each patient met specific physical examination criteria and failed to improve clinically after at least 4 wk of physical therapy. Each patient demonstrated a positive response to a fluoroscopically guided diagnostic sacroiliac joint injection. Therapeutic sacroiliac joint injections were administered in conjunction with physical therapy. Outcome measures included Oswestry scores, Visual Analog Scale pain scores, work status, and medication usage.
Patients' symptom duration before diagnostic injection averaged 20.6 mo. An average of 2.1 therapeutic injections was administered. Follow-up data collection was obtained at an average of 94.4 wk. A significant reduction (P = 0.0014) in Oswestry disability score was observed at the time of follow-up. Visual Analog Scale pain scores were reduced (P < 0.0001) at the time of discharge and at follow-up. Work status was also significantly improved at the time of discharge (P = 0.0313) and at follow-up (P = 0.0010). A trend (P = 0.0645) toward less drug usage was observed.
These initial findings suggest that fluoroscopically guided therapeutic sacroiliac joint injections are a clinically effective intervention in the treatment of patients with sacroiliac joint syndrome. Controlled, prospective studies are necessary to further clarify the role of therapeutic injections in this patient population.
探讨在荧光透视引导下对骶髂关节综合征患者进行治疗性骶髂关节注射的效果。
采用独立临床评估的回顾性研究设计。纳入31例患者；每位患者均符合特定的体格检查标准，且在至少4周的物理治疗后临床症状未改善。每位患者对荧光透视引导下的诊断性骶髂关节注射均有阳性反应。治疗性骶髂关节注射与物理治疗联合进行。疗效指标包括奥斯维斯特里评分、视觉模拟量表疼痛评分、工作状态和药物使用情况。
诊断性注射前患者症状持续时间平均为20.6个月。平均进行了2.1次治疗性注射。平均在94.4周时收集随访数据。随访时观察到奥斯维斯特里功能障碍评分显著降低（P = 0.0014）。出院时和随访时视觉模拟量表疼痛评分均降低（P < 0.0001）。出院时（P = 0.0313）和随访时（P = 0.0010）工作状态也显著改善。观察到药物使用有减少的趋势（P = 0.0645）。
这些初步研究结果表明，荧光透视引导下的治疗性骶髂关节注射是治疗骶髂关节综合征患者的一种临床有效干预措施。需要进行对照的前瞻性研究以进一步阐明治疗性注射在该患者群体中的作用。
